MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6
© Shao et al.; licensee BioMed Central Ltd. 2013
Received: 21 March 2013
Accepted: 14 May 2013
Published: 28 May 2013
MicroRNAs (miRNAs) are a large group of negative gene regulators that potentially play a critical role in tumorigenesis. Increasing evidences indicate that miR-145 acts a tumor suppressor in numerous human cancers. However, its role in oral carcinogenesis remains poorly defined. The aim of this study is to determine expression levels of miR-145 in oral squamous cell carcinomas (OSCCs) and normal mucosa tissues, and explore its biological functions in OSCCs.
Reverse transcription quantitative real-time PCR (RT-qPCR) assay was used to evaluate expression levels of miR-145. The biological functions of miR-145 were determined by cell proliferation and colony formation, cell cycle and apoptosis, as well as cell invasion assay.
MiR-145 was frequently down-regulated in OSCCs compared with normal mucosa tissues. Restoring miR-145 expression in OSCC cells dramatically suppressed cell proliferation and colony formation, and induced G1 phase arrest and cell apoptosis. Importantly, our data showed that miR-145 downregulated the expression of c-Myc and Cdk6, which have previously been identified as two direct targets of miR-145.
Our data suggest that miR-145 exerts its tumor suppressor function by targeting c-Myc and Cdk6, leading to the inhibition of OSCC cell growth. MiR-145 rescue may thus be a rational for diagnostic and therapeutic applications in OSCC.
Oral squamous cell carcinoma (OSCC) is the most common head and neck neoplasm, and the incidence of new cases indicates a continuing rise in developing countries . Although the clinical outcome of OSCC has gradually improved, the overall 5-year survival rate of patients is still disappointing [2, 3], reflecting limited advances in our understanding of the pathogenesis of this disease and the molecular events that contributed to its development. Thus, a better understanding of the molecular mechanisms driving oral carcinogenesis may lead to new diagnostic and therapeutic approaches to this disease, and improve the prognosis of OSCC patients.
Like other cancers, oral carcinogenesis involves gradual accumulation of multiple genetic and epigenetic alterations, leading to gain-of-function in oncogenes and loss-of-function in tumor suppressor genes [4, 5]. MicroRNAs (miRNAs) are a class of small non-coding RNAs, which play an important role in regulating gene function through targeting mRNAs for translational repression or degradation [6–8]. Abnormalities of miRNA have been implicated in the pathogenesis of a variety of human diseases, notably neoplasms [9–11]. Overexpression of oncogenic miRNAs or underexpression of tumor suppressor miRNAs plays a critical role in tumorigenesis. One major tumor suppressor miRNA, miR-145, which plays a crucial role in regulating smooth muscle cell differentiation  and inducing apoptosis , is downregulated in many cancers, including prostate, bladder and colon cancer, as well as B-cell malignancies [14–17]. To date, a cohort of genes related to different cancer pathways have been identified and validated as targeted genes of miR-145, such as Pai-1, Fascin1, Oct-4, Sox-2, Klf4, c-Myc, IRS1, Muc1, Yes, Stat1, and p70S6K1[18–25], suggesting that miR-145 is an oncosuppressor and plays an important role in the initiation and progression of tumor, as supported by several direct evidences that the ectopic expression of miR-145 in cancer cells leads to a loss in cell viability and induces cell death [13, 19, 26]. It has been well known that downregulation of miR-145 is caused by promoter hypermethylation in several cancers [27, 28]. Additionally, the tumor suppressor gene p53, which is inactivate in approximately 50% of human cancers, upregulates miR-145 expression, whereas the Ras oncogene downregulates its expression [28, 29]. Although downregulation of miR-145 is found in an animal OSCC model , its role in human oral carcinogenesis remains largely unknown.
In the present study, we investigated expression levels of miR-145 in primary OSCCs and adjacent normal oral tissues using reverse transcription quantitative real-time PCR (RT-qPCR). Our data showed that miR-145 was significantly downregulated in OSCCs compared with normal oral tissues. We also demonstrated the miR-145 suppressed OSCC cell growth by targeting c-Myc and Cdk6.
MiR-145 is downregulated in OSCCs
MiR-145 inhibits OSCC cell growth
MiR-145 induces OSCC cell cycle arrest and apoptosis
MiR-145 inhibits OSCC cell invasion
MiR-145 inhibits OSCC cell growth by targeting c-Myc and Cdk6
It has been well established that miRNAs play critical roles in the regulation of cell proliferation, and that miRNA dysregulation is causally involved in the initiation and progression of cancer [9–11]. The interaction networks between miRNAs and transcription regulatory pathways have added a new layer of complexity to regulate cell growth. Recently, changes of miRNA profile in cancer cells and their roles in tumorigenesis have been increasingly appreciated [32, 33]. MiR-145 has been reported to be frequently downregulated in various kinds of cancers [14–17]. However, there is presently not very much known about miR-145 involvement in oral carcinogenesis. In the present study, we attempt to investigate miR-145 expression in OSCCs and adjacent normal tissues, and explore its biological function in oral carcinogenesis. Our data show that compared with adjacent normal tissues, miR-145 expression in OSCCs is significantly downregulated, suggesting that miR-145 is a candidate tumor suppressor in the pathogenesis of OSCC.
Down-regulation or silencing of miR-145 may abolish tumor suppression so as to contribute to oral tumorigenesis. We thus test the putative tumor suppressor function of miR-145 in OSCC. MiR-145 restoration in Tca8113 cells shows significant growth-suppressing effect by inhibiting cell proliferation and colony formation in the present study. Furthermore, miR-145 re-expression induces cell cycle arrest and apoptosis, further suggesting its tumor suppressor function. These data are supported by the findings in the other cancers that the ectopic expression of miR-145 in cancer cells leads to inhibition of cell proliferation and induces cell death [13, 19, 26]. Although the evidences have highlighted the importance of miR-145 as an oncosuppressor in OSCCs, the precise molecular mechanisms remain largely unclear. To better understand the tumor suppressive effect of miR-145 in oral tumorigenesis, particularly inhibition of cell growth, we investigate the effect of miR-145 on c-Myc and Cdk6 in the present study. c-Myc plays its central role in promotion of cell replication by driving quiescent cells into the cell cycle, which is overexpressed in many cancers . This function is originally thought to be elicited mainly via activation of transcription of those c-Myc target genes that are positive regulators of the cell cycle, such as cyclins D1, D2, E and A, Cdk4, e2f1, e2f2, Cdc25A and B, etc. [34, 35]. Cdk6, one of members of the CDK family, is known to play important roles in the cell cycle though binding to cyclin D promotes the phosphorylation of tumor suppressor Rb. Following Rb phosphorylation, cyclin E activates Cdk2 to effect further phosphorylation of Rb, thereby enabling the cells to cross the G1 restriction point . In the present study, our data show that miR-145 downregulates c-Myc and its target gene cyclin D1, as supported by the findings in other cancers that miR-145 represses the expression of c-Myc and its downstream targets in colon cancer and non-small cell lung cancer (NSCLC) [21, 37]. Meanwhile, we find that miR-145 dramatically inhibits Cdk6 expression in Tca8113 cells. In line with this study, a previous study has shown that miR-145 inhibits Cdk6 expression by direct targeting its 3’-UTR in colon cancer cells . Taken together, we propose that miR-145 regulates OSCC cell growth, at least partially, by targeting c-Myc and Cdk6, and that loss of miR-145 may provide a selective growth advantage during oral carcinogenesis.
Notably, we find that miR-145 inhibits OSCC cell invasion in the present study. To be consistent with our findings, a previous study shows that miR-145 inhibits the migration of microvascular cells in response to growth factor gradients by directly targeting a transcription factor Fli-1 . Moreover, miR-145-mediated suppression of cell invasion and metastasis is in part caused by directly targeting MUC1 . A recent study also shows that miR-145 affects cell migration of glioblastoma (GB) in vitro and in vivo by directly targeting NEDD9, implicating an important role of miR-145 in GB invasion . Given the invasive ability is one of the most important features of malignancies, and one of the causes of poor prognosis, thus, miR-145 appears to be a key factor for tumor aggressiveness.
In summary, our data show that miR-145 is significantly downregulated in OSCCs compared with adjacent normal tissues. To our knowledge, the present of study is the first to demonstrate that miR-145 inhibits OSCC cell growth by targeting c-Myc and Cdk6. As this unique feature of miR-145-mediated gene silencing in human cancers, including OSCC, miR-145 may thus prove to be a potential biomarker for cancer diagnosis and serves as a new target for cancer therapy.
Materials and methods
Cell culture and tissues samples
Human OSCC cell line Tca8113 was obtained from China Center for Type Culture Collection (Wuhan, China) and routinely cultured at 37°C in RPMI 1640 medium with 10% fetal bovine serum (FBS). This study was approved by the Institutional Review Board and Human Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University School of Medicine. A total of 31 paraffin-embedded tissues, including 21 OSCC and 10 adjacent normal tissues, and 6 normal mucosa tissues were randomly obtained from the First Affiliated Hospital of Xi’an Jiaotong University School of Medicine. None of these patients received chemotherapy and radiotherapy and informed consent was obtained from each patient before the surgery. The histologic diagnosis of tumors was made and agreed upon by at least two senior pathologists at Department of Pathology of the Hospital based on World Health Organization (WHO) criteria.
The following siRNA duplexes (GenePharma Inc., Shanghai, China) were used to restore miR-145 expression: MiR-145 mimics, 5’-GUC CAG UUU UCC CAG GAA UCC CU-3’; MiRNA control, 5’-AGG UAG UGU AAU CGC CUU GTT-3’. Transfection of cells was performed using Oligofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Briefly, cells were seeded in 6-well plates at 30-40% confluence 24 h prior to transfection. MiR-145 mimics and miRNA control (30 nM each) were used for each transfection.
RNA extraction and reverse transcription quantitative real-time PCR (RT-qPCR)
RT-qPCR primers used in the present study
Primer sequences (5’-3’)
RT primer: GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACagggatt
Forward primer: CAGTGCGTGTCGTGGAGT
Reverse primer: AGGTCCAGTTTTCCCAGG
RT primer: CGCTTCACGAATTTGCGTGTCAT
Forward primer: GCTTCGGCAGCACATATACTAAAAT
Reverse primer: CGCTTCACGAATTTGCGTGTCAT
Forward primer: GCTGCTTAGACGCTGGATTT
Reverse primer: CACCGAGTCGTAGTCGAGGT
Forward primer: AGACCTTCGTTGCCCTCTGT
Reverse primer: AGTTGTTGGGGCTCCTCAG
Forward primer: TGGAGACCTTCGAGCACC
Reverse primer: CACTCCAGGCTCTGGAACTT
Forward primer: GCACAGAGCCTCGCCTT
Reverse primer: GTTGTCGACGACGAGCG
Western blot analysis
Cells were lysed in RIPA buffer. Cellular proteins were collected and subjected to 10% SDS-PAGE, and transferred onto PVDF membranes (Amersham Pharmacia Biotech, Piscataway, NJ). The membranes were then incubated with specific primary antibodies. Anti-c-Myc, anti-cyclin D1 and anti-Cdk6 were purchased from Santa Cruz Biotechnology, Inc. Anti-β-actin was purchased from Epitomics, Inc. This was followed by incubation with horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG antibodies from Santa Cruz Biotechnology, Inc., and antigen-antibody complexes were visualized using the Western Bright ECL detection system (Advansta, CA).
Cell proliferation, colony formation and anchorage independent growth assays
MTT assay was performed daily over a 3-d time course to evaluate cell proliferation. Cell culture was added with 10 μL of 5 mg/mL MTT agent (Sigma, Saint Louis, MO) and incubated for 4 h, followed by addition of 150 μL of DMSO and further 15-min incubation. The plates were then read on a microplate reader using a test wavelength of 570 nm and a reference wavelength of 670 nm.
For colony formation assay, cells (5 × 105 cells per well) were seeded in 6-well plates and transfected with miR-145 mimics or miRNA control for 24 h. The medium was refreshed every 3 days. Surviving colonies (≥50 cells per colony) were fixed with methanol, stained with 1.25% crystal violet and counted under a light microscope. For anchorage independent growth assay, 1 × 105 cells with different transfections were cultured into 6-well plates with a bottom layer of 0.6% agar and a top layer of 0.3% agar, respectively. Following the hardening of soft agar, plates were incubated at 37°C with 5% CO2. After 2 weeks of culture, colonies were photographed and counted under a light microscope.
Cell cycle analysis
Seventy-two hours after transfection, cells were harvested, washed twice in PBS, and fixed in 70% ethanol on ice for at least 30 min. Cells were then stained with propidium iodide solution (50 μg/mL propidium iodide, 50 μg/mL RNase A, 0.1% Triton-X, 0.1 mM EDTA). Cell cycles were analyzed based on DNA contents by FACS using a Flow Cytometer (BD Biosciences, NJ).
Cells were transfected with miR-145 mimics or control for 24 h. Forty-eight hours after transfection, cells were harvested and resuspended with 500 μL of binding buffer. The cell suspension was incubated with 5 μL annexin-V-FITC and propidium iodide at room temperature for 20 min. The stained cells were analyzed on a Flow Cytometer (BD Biosciences, NJ).
Cell invasion assay
Cell invasion assays were performed using Transwell chambers (8.0 μm pore size; Millipore, MA), which were coated with Matrigel (4 × dilution; 60 μL/well; BD Bioscience, NJ), in 24-well plates. Chambers were pre-coated with rat tail tendon collagen type 1 (0.5 mg/mL) on the lower surface. Transfected cells were starved overnight and then seeded in the upper chamber at a density of 2 × 105cells/mL in 400 μL of medium containing 0.5% FBS. Medium with 10% FBS (600 μL) was added to the lower chamber. Following a 24 h-incubation at 37°C with 5% CO2, non-invading cells in the upper chamber were removed with a cotton swab, and invading cells were fixed in 100% methanol and stained with 0.5% crystal violet in 2% ethanol. Photographs were taken randomly for at least four fields of each membrane. The number of invading cells was expressed as the average number of cells per microscopic field over four fields.
All the experiments were similarly done at least three times. Most of the measurements were performed in triplicate and some in duplicates. All statistical analyses were performed using the SPSS statistical package (11.5, Chicago, IL, USA). P < 0.05 was considered to be statistically significant. Unless indicated, the results shown in the figures are representatives.
This work was supported by the National Natural Science Foundation of China (No. 81272933) and the Fundamental Research Funds for the Central Universities.
- Kademani D: Oral cancer. Mayo Clin Proc. 2007, 82: 878-887. 10.4065/82.7.878.View ArticlePubMedGoogle Scholar
- de Araújo RF, Jr BCA, Clebis NK, de Moura SA, Lopes Costa Ade L: Prognostic significance of the anatomical location and TNM clinical classification in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2008, 13: E344-347.PubMedGoogle Scholar
- Scully C, Bagan J: Oral squamous cell carcinoma overview. Oral Oncol. 2009, 45: 301-308. 10.1016/j.oraloncology.2009.01.004.View ArticlePubMedGoogle Scholar
- Ha PK, Califano JA: Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. 2006, 7: 77-82. 10.1016/S1470-2045(05)70540-4.View ArticlePubMedGoogle Scholar
- Leemans CR, Braakhuis BJ, Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer. 2011, 11: 9-22. 10.1038/nrc2982.View ArticlePubMedGoogle Scholar
- Ambros V: microRNAs: tiny regulators with great potential. Cell. 2001, 107: 823-826. 10.1016/S0092-8674(01)00616-X.View ArticlePubMedGoogle Scholar
- Lee RC, Ambros V: An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001, 294: 862-864. 10.1126/science.1065329.View ArticlePubMedGoogle Scholar
- Lai EC: Micro RNAs are complementary to 3’ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002, 30: 363-364. 10.1038/ng865.View ArticlePubMedGoogle Scholar
- Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6: 857-866. 10.1038/nrc1997.View ArticlePubMedGoogle Scholar
- Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269.View ArticlePubMedGoogle Scholar
- Kent OA, Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006, 25: 6188-6196. 10.1038/sj.onc.1209913.View ArticlePubMedGoogle Scholar
- Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D: miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009, 460: 705-710.PubMed CentralPubMedGoogle Scholar
- Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sørensen KD, Ulhøi B, Borre M, Kjems J, Dyrskjøt L: miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene. 2010, 29: 1073-1084. 10.1038/onc.2009.395.View ArticlePubMedGoogle Scholar
- Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008, 27: 1788-1793. 10.1038/sj.onc.1210809.View ArticlePubMedGoogle Scholar
- Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009, 125: 345-352. 10.1002/ijc.24390.View ArticlePubMedGoogle Scholar
- Akao Y, Nakagawa Y, Naoe T: MicroRNA-143 and −145 in colon cancer. DNA Cell Biol. 2007, 26: 311-320. 10.1089/dna.2006.0550.View ArticlePubMedGoogle Scholar
- Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T: Downregulation of microRNAs-143 and −145 in B-cell malignancies. Cancer Sci. 2007, 98: 1914-1920. 10.1111/j.1349-7006.2007.00618.x.View ArticlePubMedGoogle Scholar
- Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Ørntoft TF: The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer. 2012, 106: 366-374. 10.1038/bjc.2011.520.PubMed CentralView ArticlePubMedGoogle Scholar
- Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, Nakagawa M: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010, 102: 883-891. 10.1038/sj.bjc.6605570.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009, 137: 647-658. 10.1016/j.cell.2009.02.038.View ArticlePubMedGoogle Scholar
- Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 2009, 106: 3207-3212. 10.1073/pnas.0808042106.PubMed CentralView ArticlePubMedGoogle Scholar
- Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, de Angelis T, Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 2007, 282: 32582-32590. 10.1074/jbc.M702806200.View ArticlePubMedGoogle Scholar
- Sachdeva M, Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010, 70: 378-387. 10.1158/0008-5472.CAN-09-2021.PubMed CentralView ArticlePubMedGoogle Scholar
- Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH: MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010, 5: e8836-10.1371/journal.pone.0008836.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, Jiang BH: MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012, 40: 761-774. 10.1093/nar/gkr730.PubMed CentralView ArticlePubMedGoogle Scholar
- Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X: miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010, 17: 246-254. 10.1038/cdd.2009.117.PubMed CentralView ArticlePubMedGoogle Scholar
- Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H: MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67: 8699-8707. 10.1158/0008-5472.CAN-07-1936.View ArticlePubMedGoogle Scholar
- Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G: MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 2011, 32: 772-778. 10.1093/carcin/bgr036.PubMed CentralView ArticlePubMedGoogle Scholar
- Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, Mendell JT: Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010, 24: 2754-2759. 10.1101/gad.1950610.PubMed CentralView ArticlePubMedGoogle Scholar
- Yu T, Wang XY, Gong RG, Li A, Yang S, Cao YT, Wen YM, Wang CM, Yi XZ: The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res. 2009, 28: 64-10.1186/1756-9966-28-64.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu H, Dougherty U, Robinson V, Mustafi R, Pekow J, Kupfer S, Li YC, Hart J, Goss K, Fichera A: EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res. 2011, 9: 960-975. 10.1158/1541-7786.MCR-10-0531.View ArticlePubMedGoogle Scholar
- Parpart S, Wang XW: microRNA Regulation and Its Consequences in Cancer. Curr Pathobiol Rep. 2013, 1: 71-79. 10.1007/s40139-012-0002-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Farazi TA, Hoell JI, Morozov P, Tuschl T: MicroRNAs in Human Cancer. Adv Exp Med Biol. 2013, 774: 1-20. 10.1007/978-94-007-5590-1_1.PubMed CentralView ArticlePubMedGoogle Scholar
- de Nigris F, Sica V, Herrmann J, Condorelli G, Chade AR, Tajana G, Lerman A, Lerman LO, Napoli C: c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. Cell Cycle. 2003, 2: 325-328.View ArticlePubMedGoogle Scholar
- Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999, 19: 1-11.PubMed CentralPubMedGoogle Scholar
- Sridhar J, Akula N, Pattabiraman N: Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J. 2006, 8: E204-221. 10.1208/aapsj080125.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A, Hu J: miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010, 29: 151-10.1186/1756-9966-29-151.PubMed CentralView ArticlePubMedGoogle Scholar
- Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genové G, Arrondel C, Gerwins P, Kurschat C, Schermer B: Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1. Genome Med. 2009, 1: 108-10.1186/gm108.PubMed CentralView ArticlePubMedGoogle Scholar
- Speranza MC, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M, Pellegatta S, Finocchiaro G: NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012, 3: 723-734.PubMed CentralView ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.